Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CCQWD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
MM-310
|
|||||
| Synonyms |
MM 310; MM310
Click to Show/Hide
|
|||||
| Organization |
Merrimack Pharmaceuticals, Inc.
|
|||||
| Drug Status |
Terminated in phase 1
|
|||||
| Indication |
In total 12 Indication(s)
Endometrial cancer [ICD11:2C76]
Terminated in phase 1
Gastric cancer [ICD11:2B72]
Terminated in phase 1
Head and neck squamous carcinoma [ICD11:2C31]
Terminated in phase 1
Non-small cell lung cancer [ICD11:2C25]
Terminated in phase 1
Ovarian cancer [ICD11:2C73]
Terminated in phase 1
Pancreatic cancer [ICD11:2C10]
Terminated in phase 1
Prostate cancer [ICD11:2C82]
Terminated in phase 1
Sarcoma [ICD11:2B50-2B59]
Terminated in phase 1
Small cell lung cancer [ICD11:2C25]
Terminated in phase 1
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Terminated in phase 1
Triple negative breast cancer [ICD11:2C60-2C65]
Terminated in phase 1
Urothelial cancer [ICD11:2C9Z]
Terminated in phase 1
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Ephrin type-A receptor 2 (EPHA2)
|
Antigen Info | ||||
| Payload Name |
Docetaxel
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| TTD ID | ||||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT03076372 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase-1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors. | ||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.